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Abstract
Background: Diabetes is associated with premature morbidity and mortality from its many complications. There are limited
data on the chronic complications of diabetes in children and adolescents in sub-Saharan Africa.
Objective: The study aims to determine the (1) burden and related factors of chronic systemic complications of diabetes,
including diabetic and nondiabetic ocular conditions in children and adolescents, and (2) quality of life (QoL) of participants
compared to healthy controls. This manuscript describes the study methodology.
Methods: Demographic information, medical history, anthropometric measurements, and laboratory characteristics were
collected, and the participants were screened for microvascular and macrovascular complications as well as nondiabetic ocular
disease. QoL questionnaires were administered to participants, their caregivers, and controls. Participants were followed up
annually up to 3 years to determine the natural history of and trends in these conditions. SPSS Version 25.0 will be used for data
analysis. Continuous and categorical data will be presented as mean (SD) and as percentages (%), respectively. t tests and analysis
of variance will be used to compare means, and chi-square tests will be used to compare categorical data. Correlation, regression,
and logistic regression analyses will be employed to establish linear associations and causal associations as appropriate. Relative
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risk and odds ratios will be used to estimate risk. QoL outcomes in Ghanaian children and adolescents with diabetes mellitus
compared with caregivers and healthy controls will be assessed using the Pediatric Quality of Life inventory. Significance will
be set at α=.05.
Results: Institutional approval from the Ethical and Protocol Review Committee of the University of Ghana Medical School
was received on August 22, 2014 (Protocol Identification Number: MS-Et/M.12-P4.5/2013-2014). Funding for the project was
received from the University of Ghana Research Fund (#UGRF/9/LMG-013/2015-2016) in March 2016. Patient recruitment,
clinical examination, and data collection commenced in August 2016 and was completed in September 2019. A total of 58 children
and adolescents with diabetes mellitus have been recruited. Blood samples were stored at –80 °C for analysis, which was completed
at the end of July 2020. Data analysis is ongoing and will be completed by the end of December 2020. Investigators plan to submit
the results for publication by the end of February 2021.
Conclusions: The prevalence, natural history, trends in diabetic complications and nondiabetic ocular disease, and QoL will
be provided. Our data may inform policies and interventions to improve care given to children and adolescents with diabetes.
International Registered Report Identifier (IRRID): DERR1-10.2196/21440
(JMIR Res Protoc 2021;10(1):e21440) doi: 10.2196/21440
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Introduction
Diabetes mellitus (DM), in general, is a challenge for all ages,
as it leads to significant morbidity, especially kidney, eye, heart,
and cerebrovascular disease, and premature mortality [1,2].
There are limited data on the epidemiology of DM in different
sub-Saharan African (SSA) populations [3-6]. Danquah et al
[7] reported the prevalence of type 2 DM as 6% among
Ghanaian adults in an urban area. Notably, almost all the
existing epidemiological data on DM pertain to adults [4-6].
The limited data available in children are relatively old [8-13],
and studies have reported prevalence rates of 10.1 per 100,000
[9] to 0.33 per 1000 in a Nigerian hospital [14] for children
younger than 15 years. However, considering the life expectancy
of these persons, these rates are very high. The rapid
epidemiological shift being experienced by western countries
[15,16], where overweight and obese children and adolescents
are increasingly being diagnosed with type 2 DM, may possibly
also manifest in SSA. DM predisposes to the development of
generalized microangiopathy, with clinical consequences
affecting the kidneys, eyes, and nerves, and macrovascular
disease in children and adolescents [15,17,18]. Populations of
African origin have been reported to have the highest prevalence
of microvascular complications of DM [19]. Type 1 DM is one
of the most frequent chronic diseases in children and represents
a public health challenge globally [20,21]. Reported estimates
for the prevalence of nephropathy, retinopathy, and poor growth
range between 10% and 33%, whilst hemoglobin (Hb)A1c levels
averaged 7.5%-12.5% for children and adolescents in the
western world [22-24]. However, there are limited data available
for SSA.
Although children and adolescents with type 1 DM are faced
with the threat of acute complications of hypoglycemia and
ketoacidosis on a daily basis, in the long-term, the microvascular
and macrovascular complications of the disease place them at
greatest risk for serious morbidity and earlier-than-expected
mortality [25]. The burden of both type 1 and 2 DM among
Ghanaian children and adolescents and their attendant chronic
complications have not been previously documented. Further,
nondiabetic eye conditions have not been studied in Ghanaian
children with DM. There is also a lack of information on the
natural history of diabetic complications in Ghanaian children
or how these can be modified in the Ghanaian population.
Currently, there is no national policy for the management of
DM in Ghanaian children and adolescents.
It is known that clinical characteristics of type 1 and 2 DM in
people from SSA may differ somewhat that in typical European
populations [26]. Diabetic nephropathy and diabetic retinopathy
(DR) are the leading causes of end-stage renal disease and
blindness, respectively, in younger patients globally and pose
major public health challenges. DM in children and adolescents
is becoming a health problem in developing countries. Limited
clinic-based data in Ghana suggest that the prevalence of
childhood and adolescent DM is on the increase, a trend similar
to that in ethnic minority populations in western countries [26].
To the best of our knowledge, there are limited or no data on
the occurrence of ocular and kidney disease in children with
DM in SSA including Ghana. There are no previous studies on
the choroid and retina in these children.
It has been suggested that the age of onset of type 1 DM is later
in African communities (22-29 years) including Tanzania (15-19
years), South Africa (21-30 years), and Ethiopia (20-25 years)
compared to European populations [27]. Such an
epidemiological shift from what occurs in the West is difficult
to establish in Ghana currently, due to scarce data availability
on the prevalence of type 1 or 2 DM in younger persons (<20
years).
DR is one of the long-term microvascular complications of DM
in children and leads to debilitating effects on visual acuity and
ultimately blindness in some cases [1,2]. The risk for
development of DR is said to be variable but may be present at
time of diagnosis of DM. The variability of the risk of
retinopathy is corroborated by population-based studies from
Australia and Sweden, where 24% [15] and 27% [28] of children
and adolescents with type 1 DM develop retinopathy 6 and 13
years after DM diagnosis, respectively. The incidence of DR is
dependent on age of diagnosis and duration [15,17]. Overall,
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DR affects 15%-55% of patients, with a high proportion of
proliferative retinopathy and macular edema in type 1 DM. In
adults with type 2 DM, 21%-25% have retinopathy at diagnosis
of diabetes compared with 9.5% of those with type 1 DM
[19,29]. A nationwide Danish prospective cohort study of
children and adolescents with type 1 DM followed up for 8
years investigated the effect of the prepubertal duration of DM
on the development of early retinopathy and elevated albumin
excretion rate (>20 µg/min) [22]. This Danish study reported
the prevalence of any level of retinopathy to be 17.7% in the
age group 12-15 years, 45.4% in the age group 16-20 years, and
increased to 67.6% after 20 years of age [22]. DR was
significantly associated with poor long-term glycemic control
(hemoglobin [Hb]A1c; P<.0001) and with DM duration in
patients with either a prepubertal or pubertal onset of disease
(P<.001). Prepubertal DM duration is significantly associated
with the development of DR [22].
There are also significant nonvascular diabetic eye morbidities
as younger DM patients are known to have increased risks of
developing neurotrophic keratitis, cataracts, and cranial nerve
palsies and may have refractive abnormalities, while adults may
also develop retinal vascular occlusions [2,30-33].
This study aims to determine the burden of microvascular and
macrovascular complications of diabetic and nondiabetic ocular
conditions in Ghanaian children with DM and further, to
evaluate different factors that may influence these complications
or associations. Specifically, the study will:
1. Determine the hospital-based prevalence, incidence, onset,
and trend of microvascular and macrovascular disease
(retinopathy, nephropathy, and neuropathy; cardiovascular
disease), as well as other ocular changes of diabetic
(cataracts, corneal ulceration) and nondiabetic ocular disease
in children and adolescents in Ghana.
2. Determine the relationship between the prevalence of these
microvascular and macrovascular complications with age
at diagnosis and duration of DM, HbA1c, lipid profile, and
other inflammatory markers.
3. Determine differences in the patterns of presentation of
microvascular and macrovascular complications with
nutritional status (BMI-age-sex percentile or z-score).
4. Determine the clinical, social, and biochemical determinants
of ocular, neuropathic, nephropathic, and cardiovascular
complications of juvenile DM.
5. Investigate the quality of life (QoL) of children and
adolescents living with DM compared to healthy controls
and the perspectives of their carers.
Methods
A multidisciplinary team of researchers from Europe and Ghana
is assembled to achieve the study goals. These researchers have
diverse experiences in clinic-based and population-based
research in DM and other chronic disease in both adults and
children.
Study Design
The study was done in 2 phases comprising an initial
cross-sectional study to determine the prevalence and
characteristics of microvascular and macrovascular
complications of juvenile DM as well as nondiabetic ocular
diseases among participants over a 3-year period. QoL, risks,
and interaction with other diseases including sickle cell disease
or trait will be evaluated. The second phase was a longitudinal
study in which participants from the first phase were followed
up annually for 3 years (with possible extension to 5-10 years,
subject to funding) to determine the natural history of the studied
conditions.
Study Site
The study was conducted at the outpatient clinics of the
Departments of Child Health, Medicine & Therapeutics, and
Family Medicine; the Ophthalmology Unit; and the National
Diabetes Management and Research Centre, all at Korle-Bu
Teaching Hospital (KBTH), Accra, and Cape-Coast Teaching
Hospital (CCTH) in the Central Region of Ghana. KBTH is the
national referral hospital whereas CCTH serves mainly the
Central, Western, and Western North regions of Ghana.
Study Population
Children aged 4-19 years diagnosed with DM attending the
outpatient clinics at the study sites who fulfil the inclusion
criteria, their carers, and healthy controls consisting of children
and adolescents from identified educational or religious facilities
in Accra will be included.
Case Definition
A case is defined as any child aged 4-19 years diagnosed with
DM attending the KBTH or the CCTH. DM was diagnosed in
a patient with classic symptoms and random plasma glucose
≥11.1 mmol/L. Type 1 DM was confirmed by the presence of
glutamic acid decarboxylase (GAD) antibodies, insulinopenia,
or low levels of C-peptide (stimulated C peptide values <0.6
pmol/mL), and type 2 DM was diagnosed by a negative test for
type 1 DM–specific antibodies in association with elevated
fasting insulin or C-peptide (stimulated C-peptide assay >0.6
pmol/mL) and the presence of acanthosis nigricans [34-36].
Inclusion Criteria
For the children with DM, all patients aged 4-19 years with DM
(ie, with classic symptoms of hyperglycemia or hyperglycemic
crisis, random plasma glucose ≥200 mg/dL [11.1 mmol/L]) who
consented, assented, or whose carers consented for inclusion
were included. For the healthy controls, children without DM,
any form of chronic and psychiatric diseases, or coexisting acute
disease during the study period were included.
Exclusion Criteria
Patients aged 4-19 years with DM who did not or whose parents
or guardians did not give consent for inclusion in the study were
excluded. Patients with diabetes diagnosed before 4 years of
age or after 19 years of age were also excluded. Finally, patients
with chronic disease, psychiatric disease, or coexisting acute
disease during the study period were excluded.
Sampling
Children and adolescents with DM who met the inclusion criteria
were recruited consecutively after written informed consent was
given by their carers or themselves or after assent given by the
JMIR Res Protoc 2021 | vol. 10 | iss. 1 | e21440 | p. 3https://www.researchprotocols.org/2021/1/e21440
(page number not for citation purposes)
Essuman et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX
children aged ≥8 years, as applicable. Healthy controls who met
the inclusion criteria were also recruited conveniently after
consent and assent, as applicable.
Sample Size
The population of children and adolescents attending clinics at
the study sites was expected to be low. As such, all available
patients were recruited into the study. It was estimated from
clinical data available from the proposed study sites that about
5-10 children were diagnosed with DM annually. From these
available data, with a power of 80% at a significance level of
.05, a sample size of at least 55 children was anticipated in this
study. During the period of data collection, a total of 58 children
with DM were recruited. A total of 80 age-matched healthy
controls were recruited for the QoL outcomes study.
Study Duration
An initial cross-sectional study was conducted in 2016 with
follow-up in a longitudinal study over a period of 3 years
(August 2016 to September 2019).
Procedures
General
Written informed consent or assent (see Multimedia Appendix
1) was obtained from all subjects and their guardians. This was
followed by the administration of predesigned structured
questionnaires (see Multimedia Appendix 2) to collect all
clinical data for the children and adolescents with DM. These
included patient demography, past medical history, type of DM
(type 1 or 2), features of any systemic complications
(nephropathy, cardiac, neurological, fatty liver, peripheral
vascular disease, leg ulcers, and other comorbid conditions
recorded from case notes where available), and laboratory
investigations (eg, blood glucose and HbA1c at diagnosis and
during follow-up).
Blood pressure measurements and examination of all systems
were recorded. Hb levels as well as Hb genotype status were
determined by Hb electrophoresis.
Ocular
Ocular examination included visual acuity assessment using
the appropriate LogMAR test type for age, anterior segment
assessment using slit lamp binocular microscope, dilated
fundoscopy with binocular indirect ophthalmoscopy and a 20D
or 28D lens, and fundus biomicroscopy using a 78D or 90D
lens. Ocular ultrasound (B mode) examination of the posterior
segment of the eye with a Tomey UD 1000 Model (Tomey,
Germany) was undertaken where media opacity precludes
fundus visualization. Ocular fundus photography acquiring
4-field stereocolor photos from each eye with a VISUSCOUT
100 portable retina camera system was done. All retinal images
were graded independently (according to the Early Treatment
Diabetic Retinopathy Study [ETDRS]) by WMA and VAE,
with joint adjudication when there were discrepancies. The
ophthalmic examination and investigations were repeated at
every visit (at 12-month intervals).
Systemic, Microvascular, and Macrovascular Functional
Evaluation
A full physical examination was undertaken. Height and weight
were measured, BMI was calculated in kg/m2, and BMI-age-sex
z scores and percentiles were determined using Centers for
Disease Control reference standards and Anthro Plus software.
Assessments of macrovascular and microvascular disease were
performed at baseline and annually in all study subjects. Ankle
brachial index (ABI) was measured according to the American
Heart Association guidelines [37]. Huntleigh Doppler equipment
with an 8-MHz Doppler probe (Huntleigh, UK) was used to
determine flow reappearance during slow deflation of a blood
pressure cuff. The systolic pressure of the posterior tibial and
dorsalis pedis was measured in both ankles, and the higher of
the 2 was used as the ABI numerator. The denominator was
determined by the higher of the 2 systolic blood pressure
readings, 1 taken from each arm. An ABI ≤0.90 was indicative
of peripheral arterial disease. Assessment of coronary artery
disease using a resting 12-lead electrocardiogram (Nova
PC-based ECG system) was done and analyzed using the
Minnesota Code. Clinical assessment of neuropathy included
a physical examination as well as an assessment of vibration
perception threshold (VPT) as recommended by the American
Diabetes Association [38]. VPT was assessed using a hand-held
neurothesiometer (Horwell Neurothesiometer, Scientific
Laboratory Supplies Ltd, Nottingham, UK) according to the
manufacturer’s guidelines. VPT was assessed at the
metatarsophalangeal joint of both feet in a 2-step manner starting
from 0 V with increasing stimulation and then starting from 50
V with decreasing stimulation.
Laboratory Investigations
Laboratory assessments were performed at the Diabetes
Research and Chronic Disease Reference Laboratory, University
of Ghana Medical School, and MDS-Lancet Laboratories Ghana
Limited in Accra. Samples of serum and plasma aliquoted from
appropriate collection tubes or whole blood from the
collaborating regional hospitals were transported to the Diabetes
Research and Chronic Disease Reference Laboratory on dry ice
within 12 hours after sample acquisition and processed
immediately or stored at –80 °C for later analysis. Type 1 DM
was confirmed by the presence of GAD antibodies,
insulinopenia, or low levels of C-peptide, and type 2 DM was
diagnosed by a negative test for type 1 DM–specific antibodies
in association with elevated fasting insulin or C-peptide and the
presence of acanthosis nigricans. Blood C-peptide levels were
determined by competitive enzyme immunoassay methods using
ELISA kits (NovaTec Immundiagnostica GmbH, Dietzenbach,
Germany). Islet cell antibodies were assayed using ICA Enzyme
Immuno Assay Kits. Furthermore, GAD65 autoantibodies were
assayed using another ELISA kit (Medizym anti-GAD Testkit
96 tests, Medipan GmbH, Blankenfelde-Mahlow, Germany).
Presence and levels of thyroid antibodies were determined using
a chemiluminescent microparticle immunoassay (Abbott Alinity,
Abbott Park, IL). HbA1c was measured using the Tri-Stat
Boronate Affinity System (Trinity Biotech, Ireland). Lipid
profile was assayed by determining the total serum cholesterol
(cholesterol oxidase, esterase), triglycerides (enzymatic end
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point), high-density lipoprotein cholesterol (direct measure
polymer-polyanion), and low-density lipoprotein cholesterol
by enzymatic methods using an automated chemistry analyzer
(AU480 Beckman Coulter, Brea, CA). Nephropathy was
assessed by the measurement of albuminuria using
immunochromatography on fresh spot urine, and serum beta 2
macroglobulin was assessed by an immunoassay method
(Siemens Immulite, Washington DC). Blood urea (urease UV
method), electrolytes (ion selective electrodes [ISE] and
enzymatic method for bicarbonates), and creatinine (Jaffe
IDMS-traceable method) were assayed with the Beckman
Coulter AU480. Hb electrophoresis was performed to determine
the Hb type using the cellulose acetate paper method (tris-EDTA
boric acid [TEB] buffer, pH 8.4). Urinalysis and microscopic
examination of urine deposits were performed. Hematological
examination included a complete blood count using a 3-part
Mindray hematology autoanalyzer (Shanghai, China).
Other Investigations
Abdominal ultrasound (B mode) was performed on patients
found to have abdominal masses on clinical examination at
baseline then yearly using a Hitachi EUB-7500 (Japan-made,
2009-2010). Where there was a pathology detected on
ultrasound, magnetic resonance imaging was performed with
the Hitachi Airis Elite (Ibaraki, Japan).
Quality of Life Outcome
Children and adolescents with DM and healthy controls
completed the Pediatric Quality of Life Inventory (PedsQL,
Mapi Research Trust, Lyon, France; Multimedia Appendix 3).
In addition, children and adolescents with DM completed the
disease-specific (diabetes) module. Parents and carers also
completed the proxy reports for the PedsQL 4.0 Generic Core
Scales and the disease-specific (diabetes) modules, the PedsQL
2.0 Family Impact Module, and the PedsQL Family Information
Form. Permission was sought from Mapi Research Trust for
the use of the inventories (Multimedia Appendix 4). Each
questionnaire took approximately 5-10 minutes to complete.
The PedsQL 4.0 Generic Core Scales has a set of questions for
the participants and their parents or carers and healthy controls.
For the participants and controls, the PedsQL asks questions
about how they felt and what they thought about their health.
For the parent, the PedsQL assesses the health-related QoL
(HRQoL) of their children and adolescents. It contains questions
about the child’s physical, emotional, social, and school
functioning in the past 1 month. It is a 5-point Likert scale
ranging from 0 (Never) to 4 (Almost Always) without weighting
of items on the scale.
The PedsQL 3.2 Diabetes Module is a 33-item diabetes-specific,
HRQoL instrument that is made up of 5 scales measuring
diabetes symptoms (15 items), treatment barriers (5 items),
treatment adherence (6 items), worry (3 items), and
communication (4 items). The scale is made up of patient
self-report and parent proxy report formats for ages 5-25 years
and a parent proxy report format for ages 2-4 years, which
analyzes the patient’s and parent’s perceptions of the patient’s
diabetes-specific symptoms and management challenges. The
patient self-report aspect was designed specifically for ages 5-7
years, 8-12 years, 13-18 years, and 18-25 years, while the parent
proxy report forms are specific for ages 2-4 years (toddler), 5-7
years (young child), 8-12 years (child), 13-18 years (adolescent),
and 18-25 years (young adult). The instrument seeks to know
how much of a problem each item has been during the past 1
month. Items on the scale are reverse-scored and linearly
transformed to a 0-100 scale (where 0=100, 1=75, 2=50, 3=25,
4=0). Lower scores indicate more diabetes symptoms and
management problems, meaning lower diabetes-specific
HRQoL. Summary scores are calculated as the sum of all the
items divided by the number of items answered. When more
than 50% of the items in the scale are missing, the summary
score is not calculated.
The PedsQL 2.0 Family Impact Module is a 36-item tool that
examines parents' self-reported HRQoL and family functioning
due to their child’s health condition. The tool is made up of
physical functioning (6 items), emotional functioning (5 items),
social functioning (4 items), cognitive functioning (5 items),
communication (3 items), worry (5 items), daily activities (3
items), and family relationships (5 items) of the parent or carer.
The PedsQL Family Information Form was completed by the
parent or carers. The form is made up of the demographic
characteristics of the child and parent and an impact scale
assessment. Demographic characteristics such as age, sex, and
ethnicity of the child and marital status, highest level of
education, and occupation of both parents are documented. For
the impact scale assessment, the presence of a chronic condition
(defined as a physical or mental health condition that has lasted
or is expected to last at least 6 months and interferes with the
child’s activities) in the past 6 months, any overnight visit to
the hospital or an emergency room or urgent care in the past 12
months, absenteeism from school in the past 30 days due to
physical or mental health conditions, number of days in the past
30 days the child was sick in bed or too ill to play and needed
someone to care for them due to a health condition, and parent’s
absenteeism from work due to child’s ill health were all
documented.
Preliminary or Pilot Data
Our anecdotal clinical experience is that the prevalence of
childhood and adolescent DM is on the increase and that
complications including DR and nephropathy may be severe.
This is based on the collective experiences of the physicians
and ophthalmologists involved in this project as well as national
projections.
Primary Outcome Measures
The primary outcomes are the prevalence of DM in the young
(4-19 years old) and occurrence of organ-specific complications
(ie, nephropathy, retinopathy, and neuropathy) in this population.
Secondary Outcome Measures
Secondary outcomes include incidence of diabetic complications
from baseline to the end of the second year of the study, QoL
and type of comorbid conditions, weight and height (for
nutritional status using BMI-age-sex percentile and z-score),
Hb levels and genotypes, and duration and number of follow-ups
in the study.
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Disease progression will also be evaluated, including incidences
of nephropathy, retinopathy, visual loss, neuropathy, and
peripheral arterial disease. Changes in the macular, retinal, and
choroidal thickness at onset of DR and with time will be
assessed and correlated with other parameters.
Treatment of Identified Cases
All children with diseases or complications requiring treatment
were treated or will be treated by the relevant specialty using
medication and other treatment modalities used and prescribed
routinely in Ghana as per Ghana Health Service or Teaching
Hospital treatment policies as well as those of the National
Health Insurance Scheme. There is currently no national policy
for the management of DM in Ghanaian children and
adolescents. As such, international guidelines for the
management of children and adolescents with DM were also
referred to, as necessary, including the American Diabetes
Association Guidelines [36] and the Diagnosis and Management
Guideline for Diabetes (type 1 and type 2) in children and young
people (NICE, NG18) [39].
Follow-Up of Patients in the Longitudinal Study
Follow-up visits for participants without ocular complications
were scheduled annually. For participants with ocular
complications at baseline or diagnosed during annual follow-up
visits, subsequent follow-up examinations were scheduled for
every 6-12 months as determined by the type and severity of
the findings.
Study Status
Currently, patient recruitment, clinical examinations, and some
laboratory analysis have been completed. Blood samples are
stored at –80 °C for analysis. Data captured to date have been
cleaned for analyses.
Ethical Approval
This study was approved by the Ethical and Protocol Review
Committee of the College of Health Sciences, University of
Ghana (protocol identification number:
MS-Et/M.12-P4.5/2013-2014).
Data Analysis
Data captured using Microsoft Office Access will be cleaned
for analysis. Analysis will be done using SPSS Version 25.0.
Continuous numerical data will be presented as mean (SD) and
categorical data as percentages (%). For continuous variables
that may be skewed, median and interquartile ranges will be
used for their summary. Data will be presented as frequency,
proportions, and percentages either in tables or pie and bar charts
as appropriate. Chi-square tests will be used to compare
proportions and tests for independence or associations of
conditions among the categories of patients. t tests and analyses
of variance will be used to compare means where appropriate.
Correlation analysis will be used to establish linear associations
for scale and ordinal variables, while regression and logistic
regression analyses will be employed to establish causal
associations in the data. Relative risk and odds ratios will be
used to estimate risk in the samples. Significance will be set at
α=.05.
QoL outcomes in Ghanaian children and adolescents with DM
compared with parents or carers and healthy controls will be
assessed using the PedsQL 4.0 Generic Core Scales inventory.
In scoring the process, items on the inventory will be
reverse-scored and linearly transformed to a 0-100 scale as
follows: 0=100, 1=75, 2=50, 3=25, 4=0. When >50% of the
items in the scale are missing, the scale scores will not be
computed. When ≥50% items are completed, the mean of the
completed items in the scale will be computed by summing the
items over the total number of items answered. The Psychosocial
Health Summary Score will be obtained by the summation of
the items over the number of items answered in the Emotional,
Social, and School Functioning Scales. The total score will
finally be obtained by summing all the items over the number
of items answered on all the scales.
To examine parents' self-reported HRQoL and family
functioning due to their children’s health condition, the PedsQL
2.0 Family Impact Module will be used. The overall total score
will be obtained by averaging all 36 items. To obtain the
HRQOL summary score of a parent, the average of the 20 items
comprising the Physical, Emotional, Social, and Cognitive
Functioning scales will be computed. The Family Functioning
Summary score will be calculated by averaging the 8 items
comprising the Daily Activities and Family Relationships scales.
The items on the Family Impact Module will be reverse-scored
and transformed linearly to a 0-100 scale where the higher scores
will show better (a less negative impact of the child’s health on
the parent or family) HRQoL.
Results
Institutional approval from the Ethical and Protocol Review
Committee of the University of Ghana Medical School was
received on August 22, 2014 (protocol identification number:
MS-Et/M.12-P4.5/2013-2014). Funding for the project was
received from the University of Ghana Research Fund
(#UGRF/9/LMG-013/2015-2016) in March 2016.
Patient recruitment, clinical examination, and data collection
commenced in August 2017 and were completed in September
2019. A total of 58 children and adolescents with DM has been
recruited. Blood samples are stored at –80 °C for analysis, which
was completed at the end of July 2020.
Data analysis is ongoing and will be completed by the end of
December 2020. Investigators plan to submit the results for
publication by the end of February 2021.
Discussion
The population of SSA is rapidly expanding. Similarly, the
prevalence of DM is reported to be on the increase, increasing
the risks associated with increased population growth compared
to the risk reduction in higher-income economies [40]. This
increase in DM prevalence is faster in low-income and
middle-income populations than in high-income populations in
all age groups [41].
Clinical studies in adults from South Africa [42], Tanzania [12],
Ethiopia [43], and Ghana [7,44] reviewed by Hall et al [26]
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suggest that the characteristics of type 1 and 2 DM in people
from SSA may differ somewhat from typical European
populations. It is suggested that the present study, when
completed, will help elucidate any such differences in childhood
and adolescent DM in SSA including Ghana. Children and
adolescents with type 1 DM are threatened by acute
complications of hypoglycemia and ketoacidosis on a daily
basis. However, the long-term microvascular and macrovascular
complications of the disease place them at greatest risk for
serious morbidity and early mortality [25].
Although it is estimated that the prevalence of DM in the adult
population of Ghana is approximately 10%, no data are available
on childhood and adolescent DM in Ghana. However, when
DM is coupled with the number of years ahead of persons in
childhood and adolescence, morbidity and the drain on the
individuals, their families, and society become very immense
and require quantification. In order to establish the importance
of this growing problem, it is important to determine the
hospital-based prevalence, incidence, onset, and trends of
neuropathy, microvascular and macrovascular diseases
(retinopathy, nephropathy, and neuropathy; cardiovascular
disease), and other changes of diabetic (cataracts, corneal
ulceration) and nondiabetic ocular disease in children and
adolescents in Ghana. Potential estimates of hospitalization and
mortality may also be gleaned from this study. This will serve
as a preamble to further investigate the population prevalence
and trend of DM in Ghana. To the best of our knowledge, there
are no data on the QoL of children and adolescents with DM in
SSA. This study, when completed, will provide some data to
fill such a void. The associations with obesity, as well as QoL
of people with DM and their carers, will be of immense
importance in national and SSA planning of health education
programs on DM and other childhood morbidities.
Furthermore, nondiabetic eye diseases have not been previously
studied in Ghanaian children with DM. In addition, there is a
lack of information on the natural history of DM complications
in Ghanaian children or how these can be modified in the
Ghanaian population. Currently, there is no national policy for
the management of DM in Ghanaian children and adolescents.
Data from this study would therefore lead to the development
of policy briefs and guidelines that will be submitted to the
Ministry of Health to help with the planning and implementation
of effective policies for DM screening and the early detection
of diabetic complications and nondiabetic eye disease in
children, for improved care.
The study may also offer an opportunity for training and
mentorship of resident doctors and biomedical scientists to
augment in building capacity toward clinical care and research
in children and adolescents with DM.
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